Preclinical News and Research

RSS
Pharmatek to install the Xcelodose automated encapsulator system in San Diego

Pharmatek to install the Xcelodose automated encapsulator system in San Diego

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Array BioPharma to present poster on ARRY-403 glucokinase activator

Array BioPharma to present poster on ARRY-403 glucokinase activator

Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody

Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody

Phase 1 clinical trial to test safety and activity of human MAB launched in India

Phase 1 clinical trial to test safety and activity of human MAB launched in India

Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer

Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer

FASgen receives $1.4 million SBIR Phase II NIH grant for obesity research

FASgen receives $1.4 million SBIR Phase II NIH grant for obesity research

Social environment plays vital role in breast cancer

Social environment plays vital role in breast cancer

Raptor and TorreyPines Therapeutics announce merger completion

Raptor and TorreyPines Therapeutics announce merger completion

Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting

Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting

Amicus Therapeutics to initiate Phase 1 study of AT2220

Amicus Therapeutics to initiate Phase 1 study of AT2220

Parathyroid gland transplants may prevent untreatable form of bone loss

Parathyroid gland transplants may prevent untreatable form of bone loss

Reuters examines how HIV vaccine trial results will guide future studies

Reuters examines how HIV vaccine trial results will guide future studies

Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies

Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies

Ligand and GSK amend agreement to pursue independent research programs

Ligand and GSK amend agreement to pursue independent research programs

NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis

NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis

Preclinical data of CardiAQ Valve Technologies' TMVI in vivo study presented at the TCT 2009

Preclinical data of CardiAQ Valve Technologies' TMVI in vivo study presented at the TCT 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Central metabolic network model of Thermotoga maritima bacterium developed

Central metabolic network model of Thermotoga maritima bacterium developed

RXi Pharmaceuticals acquires self-delivering rxRNA technology platform from Advirna

RXi Pharmaceuticals acquires self-delivering rxRNA technology platform from Advirna

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.